The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2025.04.119 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Morgan C H Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: morgan.cheng25@imperial.ac.uk. Hauptthemen laut MEDLINE: Ketamine, Major Depressive Disorder, Quality of Life, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, National Natural Science Foundation of China, Milken Institute.
Themen: Depression
Abstract (Originalsprache)
INTRODUCTION: The rapid and clinically meaningful antidepressant effects of ketamine and esketamine are well-established in major depressive disorder (MDD) and treatment-resistant depression (TRD) as evidenced by improvement in clinician- and patient-reported depression measures. However, there remains a need to determine how these agents affect patient-reported quality of life (QoL). Herein, we aimed to systematically review extant studies evaluating the effect of ketamine and esketamine on QoL measures. METHODS: A literature search was conducted on online databases (PubMed, Scopus, Web of Science, Medline, and clinicaltrials.gov) for articles from inception to September 30th, 2024, reporting on the association between ketamine/esketamine and measures of QoL in persons diagnosed with MDD or TRD. A risk of bias assessment was conducted using the ROBINS-1 tool and the Newcastle-Ottawa Scale. RESULTS: Five studies were identified that investigated the association between ketamine/esketamine and measures of QoL in persons with MDD or TRD. Scales used to measure QoL included the WHOQOL-BREF scale, Assessment of Quality of Life 8D test, and the EuroQol-5 Dimension-5 Layers. Statistically significant findings (p < 0.001) suggest that ketamine and esketamine improve measures of QoL in persons with MDD or TRD. However, an overall moderate risk of bias was observed in the papers included in this analysis. DISCUSSION: Extant studies suggest that ketamine and esketamine treatment are associated with improvement in QoL measures in adults with MDD or TRD. Limitations of this study include hetergeneity in the types of QoL scales as well as study study duration among the studies included. Near-term research priorities should endeavour to investigate the effect of ketamine and esketamine on specific domains of QoL, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: morgan.cheng25@imperial.ac.uk.
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: christine.dri@mail.utoronto.ca.
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: hana.ballum@mail.utoronto.ca.
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Mood Disorder and Psychopharmacology Unit, University Health Network,…
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: will.cheung@mail.utoronto.ca.
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: kayla.teopiz@alumni.utoronto.ca.
Förderung
- Canadian Institutes of Health Research
- National Natural Science Foundation of China
- Milken Institute
- Global Alliance for Chronic Diseases
- AbbVie Canada
Zitieren
APA
Cheng, M. C. H., Dri, C. E., Ballum, H., Valentino, K., Cheung, W., Teopiz, K. M., Wong, S., & McIntyre, R. S. (2025). The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.04.119
Vancouver
Cheng MCH, Dri CE, Ballum H, Valentino K, Cheung W, Teopiz KM, et al. The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.04.119
BibTeX
@article{Cheng2025,
author = {Cheng, Morgan C H and Dri, Christine E and Ballum, Hana and Valentino, Kyle and Cheung, William and Teopiz, Kayla M and Wong, Sabrina and McIntyre, Roger S},
title = {The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2025.04.119}
}
EUVIMED